Top News The 19th JPMA Forum" was held.
The “JPMA Forum” is held once a year with the aim of deepening understanding of the pharmaceutical industry through frank exchanges of views among representatives from various sectors closely tied to the industry and representatives from member companies.In 2019, the “19th JPMA Forum” was held on November 7 at the Keidanren Hall Conference Center (Chiyoda Ward, Tokyo). For this event, we invited Mr. Yasuhiro Fujiwara, who assumed the position of PMDA Chief Executive in April 2019, to deliver a keynote address.
Scene at the venue
Part I. Lectures
The content of the lecture titled “PMDA’s New Initiatives: Toward Realizing the ‘4 Fs (Firsts)’” by Mr. Yasuhiro Fujiwara, PMDA Chief Executive, is as follows.
The Pharmaceuticals and Medical Devices Agency (PMDA), an independent administrative agency, is responsible for "health hazard remedies" based on the "Pharmaceuticals and Medical Devices Agency Act (PMDA Act)" and the "Act on Quality, Efficacy and Safety Assurance of Pharmaceuticals, Medical Devices and Other Products (Pharmaceuticals and Medical Devices Act) The PMDA was established in 2004, and at the time of its establishment, the pharmaceutical administration was facing various challenges, such as the "drug lag". However, by strengthening its organization and taking other actions, the PMDA has grown into an organization that is on par with regulatory authorities in Europe and the U.S., and has maintained one of the world's longest review periods for new drugs, enabling it to conduct highly predictable reviews.
Mr. Yasuhiro Fujiwara, PMDA Chief Executive
In FY2019, we have just started our operations based on the Fourth Medium-Term Plan, and it is necessary for us to take on various challenges to further improve the quality of our operations without stopping our progress to date. We will focus on the four "Fs" ("Patient First," "Access First," "Safety First," and "Asia First").
In order to realize the four "Fs," the PMDA must make the best decisions in each of its operations, taking into account the scientific evaluation of risks and benefits over time and the efficacy and safety of products while keeping the clinical field in mind, respond to innovative technologies based on the latest science, improve transparency and provide accurate information to the medical field, patients, and the public, and provide a high quality of service to the public. Various efforts are required to improve transparency and provide accurate information to the medical community, patients, and the public.
In particular, as specific efforts to respond to innovative technologies and products, we have implemented the "Pioneer Review Designation System," "Conditional Accelerated Approval System for Pharmaceuticals," and "Conditional and Time-Limited Approval System for Regenerative Medicine Products" for the early commercialization of new drugs and regenerative medicine products, and also established the Regulatory Science Center and established the "Scientific Committee" and "Scientific Committee" for the early commercialization of regenerative medicine products. In addition, the Pharmaceuticals Association of Japan (PAK) has established the Regulatory Science Center, which aims to improve its ability to respond to innovative technologies through the implementation of the "Scientific Committee" and "Horizon Scanning" programs.
The JPMA is an association of R&D-oriented pharmaceutical companies that aims to contribute to the improvement of human health in Japan and around the world through the development of innovative and highly useful pharmaceutical products and the sound growth of the pharmaceutical industry. Safety First," "Asia First," and "Patient First") are exactly the path that the JPMA should take.
Part II Round-table Discussion
At the roundtable discussion, following opening remarks by Mr. Joji Nakayama, Chairman of the JPMA, guest addresses were delivered by Mr. Toshifumi Kojima, Parliamentary Secretary to the Minister of Health, Labor and Welfare, representing the Ministry of Health, Labor and Welfare; Mr. Yutaka Hatori, Standing Director of the Japan Medical Association;Mr. Nobuo Yamamoto, President of the Japan Pharmacists Association; and Mr. Shinsuke Amano, Chairman of the National Federation of Cancer Patient Organizations, representing patient groups, delivered guest addresses.
Minister of Health, Labour and Welfare Mr. Toshifumi Kojima
Executive Director, Japan Medical Association Dr. Yutaka Hatori
Japan Pharmacists Association, President
Mr. Nobuo Yamamoto
National Federation of Cancer Patient Organizations Chairman Shinsuke Amano
Japan Pharmaceutical Manufacturers Association (JPMA)
Chairman Joji Nakayama
The banquet began with a toast led by Mr. Isao Teshirogi, Chairman of the Japan Pharmaceutical Manufacturers Association. Subsequently, a larger-than-usual number of members of the Diet shared words of expectation and encouragement for the pharmaceutical industry. The packed venue was filled with the enthusiasm of the many participants, and lively conversations spread throughout the hall.Even after the closing remarks by Yasufumi Okada, Vice Chairman of the JPMA, the lively conversation continued, and the “19th JPMA Forum” concluded successfully as a resounding success.
Japan Pharmaceutical Manufacturers Association, Chairman Mr. Isao Teshirogi
JPMA
Yasufumi Okada, Vice Chairman
Scene of the Roundtable Meeting
(The 19th Pharmaceutical Manufacturers Association Forum was a great success.)
